IL-22, on the other hand, protects against TGF-β1-induced renal fibrosis and inflammation by activating the Jagged1/Notch1 signaling pathway, thereby effectively delaying the pathological progression of AKI to CKD in vitro [193]. This evidence concerns the gene TGFB1 and chronic kidney disease.